Penumbra, Inc. (PEN)
USD 238.9
(-3.49%)
USD 238.9
(-3.49%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 111.99 Million USD | 1985.84% |
| 2022 | 6.08 Million USD | 181.08% |
| 2021 | 7.83 Million USD | 80.74% |
| 2020 | -22.34 Million USD | -181.97% |
| 2019 | 47.5 Million USD | -21.88% |
| 2018 | 36.15 Million USD | 5120.43% |
| 2017 | 4.94 Million USD | 186.3% |
| 2016 | 947 Thousand USD | -132.3% |
| 2015 | 5.93 Million USD | 11.14% |
| 2014 | 3.76 Million USD | 937.42% |
| 2013 | -449 Thousand USD | -113.1% |
| 2012 | 3.42 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 19.62 Million USD | -50.66% |
| 2024 Q3 | 44.26 Million USD | 163.34% |
| 2024 Q2 | 3.63 Million USD | -456.18% |
| 2023 Q1 | 8 Million USD | 65.69% |
| 2023 Q2 | 17.88 Million USD | 123.39% |
| 2023 Q4 | 31.69 Million USD | -43.4% |
| 2023 Q3 | 55.98 Million USD | 212.97% |
| 2023 FY | - USD | 1985.84% |
| 2022 Q3 | 11.65 Million USD | 101.36% |
| 2022 Q4 | 4.83 Million USD | -58.55% |
| 2022 FY | - USD | 181.08% |
| 2022 Q1 | 1.68 Million USD | 104.19% |
| 2022 Q2 | 5.79 Million USD | 244.64% |
| 2021 Q1 | 16.93 Million USD | 1070.43% |
| 2021 Q2 | 13.86 Million USD | -18.14% |
| 2021 Q3 | 12.41 Million USD | -10.45% |
| 2021 FY | - USD | 80.74% |
| 2021 Q4 | -40.05 Million USD | -422.68% |
| 2020 Q2 | -14.51 Million USD | -506.78% |
| 2020 FY | - USD | -181.97% |
| 2020 Q4 | -1.74 Million USD | 91.34% |
| 2020 Q3 | -20.15 Million USD | -38.85% |
| 2020 Q1 | 3.56 Million USD | -66.26% |
| 2019 Q4 | 10.57 Million USD | -29.61% |
| 2019 Q3 | 15.02 Million USD | 2.0% |
| 2019 Q2 | 14.73 Million USD | 13.72% |
| 2019 Q1 | 12.95 Million USD | 94.27% |
| 2019 FY | - USD | -21.88% |
| 2018 Q4 | 6.66 Million USD | -84.25% |
| 2018 Q2 | 10.83 Million USD | 98.97% |
| 2018 Q1 | 5.44 Million USD | 41.18% |
| 2018 FY | - USD | 5120.43% |
| 2018 Q3 | 42.33 Million USD | 290.81% |
| 2017 FY | - USD | 186.3% |
| 2017 Q4 | 3.85 Million USD | 109.45% |
| 2017 Q3 | 1.84 Million USD | 428.75% |
| 2017 Q2 | -560 Thousand USD | 59.77% |
| 2017 Q1 | -1.39 Million USD | -20.83% |
| 2016 Q3 | -700 Thousand USD | -1029.03% |
| 2016 Q1 | 2.37 Million USD | 30.38% |
| 2016 Q2 | -62 Thousand USD | -102.61% |
| 2016 Q4 | -1.15 Million USD | -64.57% |
| 2016 FY | - USD | -132.3% |
| 2015 Q1 | 4.32 Million USD | 682.64% |
| 2015 FY | - USD | 11.14% |
| 2015 Q4 | 1.82 Million USD | -31.68% |
| 2015 Q3 | 2.66 Million USD | 178.21% |
| 2015 Q2 | -3.4 Million USD | -178.7% |
| 2014 Q4 | 553 Thousand USD | 9.94% |
| 2014 Q2 | 702 Thousand USD | -64.94% |
| 2014 FY | - USD | 937.42% |
| 2014 Q3 | 503 Thousand USD | -28.35% |
| 2014 Q1 | 2 Million USD | 0.0% |
| 2013 FY | - USD | -113.1% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott Laboratories | 10.46 Billion USD | 98.93% |
| Allurion Technologies Inc. | -69.03 Million USD | 262.24% |
| Artivion, Inc. | 38.14 Million USD | -193.629% |
| Avanos Medical, Inc. | 53.2 Million USD | -110.519% |
| Butterfly Network, Inc. | -124.84 Million USD | 189.709% |
| Butterfly Network, Inc. | -124.84 Million USD | 189.709% |
| Bio-Rad Laboratories, Inc. | -608.26 Million USD | 118.412% |
| Boston Scientific Corporation | 3.45 Billion USD | 96.757% |
| Perspective Therapeutics, Inc. | -14.83 Million USD | 854.792% |
| CONMED Corporation | 182.18 Million USD | 38.527% |
| Edwards Lifesciences Corporation | 1.76 Billion USD | 93.664% |
| Paragon 28, Inc. | -36.61 Million USD | 405.883% |
| Glaukos Corporation | -82.11 Million USD | 236.388% |
| Globus Medical, Inc. | 418.23 Million USD | 73.222% |
| Inspire Medical Systems, Inc. | -17.06 Million USD | 756.483% |
| Integer Holdings Corporation | 282.05 Million USD | 60.293% |
| Medtronic plc | 9.05 Billion USD | 98.763% |
| Nevro Corp. | -78.31 Million USD | 243.016% |
| Owlet, Inc. | -27.48 Million USD | 507.421% |
| Vicarious Surgical Inc. | -69.19 Million USD | 261.863% |
| Smith & Nephew plc | 979 Million USD | 88.56% |
| Sonendo, Inc. | -54.76 Million USD | 304.492% |
| STERIS plc | 1.41 Billion USD | 92.071% |
| Stryker Corporation | 5.16 Billion USD | 97.83% |
| Vapotherm, Inc. | -34.35 Million USD | 425.977% |
| Zimmer Biomet Holdings, Inc. | 2.44 Billion USD | 95.427% |